Nalmefene (Selincro®)

Assessment Status Assessment Process Complete
Drug Nalmefene
Brand Selincro®
Indication Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.
Assessment Process
Rapid review commissioned 07/06/2013
Rapid review completed 28/06/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 21/10/2013
NCPE assessment completed 08/04/2014
NCPE assessment outcome Reimbursement Recommended

Technical Summary

The NCPE consider this to be a cost effective product for the defined patient population in combination with psychosocial intervention.